A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
This study is an open-label, single-Arm， phase II clinical trial of a Chinese Patent Medicine Yangzheng Xiaoji Capsule to improve the adverse reaction nausea of Niraparib in the first-line maintenance treatment in advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
Ovarian Cancer
DRUG: Yangzheng Xiaoji|DRUG: Niraparib
Incidence of nausea, all grade of nausea base on CTCAE V5.0, 3 cycles (each cycle is 28 days)
Quality of life changes, base on Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) score, 3 cycles (each cycle is 28 days)|PFS rate, PFS, OS and overall response rate (ORR, Overall response rate) at 12, 18 and 24 months, PFS rate, PFS, OS and overall response rate (ORR, Overall response rate) at 12, 18 and 24 months in patients with advanced ovarian cancer maintained on chemotherapy combined with bevacizumab switched nilaparib, up to 24 months
Incidence of anemia, thrombocytopenia, and neutropenia, Incidence of All Grade Anemia, Thrombocytopenia, Neutropenia within 3 Cycles (CTCAE V5.0), 3 cycles (each cycle is 28 days)|Incidence of fatigue, Incidence of All Grade Fatigue Over 3 Cycles (CTCAE V5.0), 3 cycles (each cycle is 28 days)
This study will investigate a Chinese Patent Medicine Yangzheng Xiaoji Capsule improve the adverse reaction nausea of Niraparib in the first-line maintenance treatment in advanced EOC, who have previously received ≥ 3 cycles of prior combined bevacizumab chemotherapy and a complete or partial response with platinum-based chemotherapy.

Approximately 50 eligible subjects are planned to be enrolled, given Yangzheng Xiaoji Capsule and niraparib maintenance treatment.

The dosing regimen is:Niraparib 200mg QD combined with Yangzheng Xiaoji Capsule 0.36g\*4 tid，28 days/cycle. Subjects will receive Niraparib plus Yangzheng Xiaoji Capsule up to 3 cycles.